Research programme: angiogenesis inhibitors - SUGEN/Allergan

Drug Profile

Research programme: angiogenesis inhibitors - SUGEN/Allergan

Alternative Names: Angiogenesis inhibitors research programme - SUGEN/Allergan; Eye disorders therapy - SUGEN/Allergan; Research programme: eye disorders therapy - SUGEN/Allergan

Latest Information Update: 28 Feb 2008

Price : $50

At a glance

  • Originator Allergan; SUGEN
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Eye disorders

Most Recent Events

  • 30 Apr 2003 No development reported - Preclinical for Eye disorders in USA (unspecified route)
  • 16 Apr 2003 On 16 April 2003, Pharmacia Corporation was acquired by, and merged into, Pfizer
  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top